HIV / AIDS

Here is a case study involving a patient with the virus and the clinical approach in thinking about appropriate treatment while keeping stewardship in mind.

The role of the US President’s Emergency Plan for AIDS Relief in combating tuberculosis (TB).

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

Study proves the role of harnessing CrAgSQ for management over the infection.

Defense against omicron in HIV-positive patients post-COVID.

Both the use of a vaginal ring or oral pre-exposure prophylaxis were found to be safe for HIV prevention throughout pregnancy.

Biomarkers associated with mortality differed by sex and there may be distinct pathophysiologic mechanisms that account for the increased risk seen in females, according to investigators.

Unraveling monocyte activation and the implications for cardiovascular risk

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

A National Institutes of Health (NIH) sponsored study reveals a need for more accurate screening in Black people and cisgender women.

Study shows high efficacy of a 4-week glecaprevir/pibrentasvir regimen for shorter, more manageable treatment duration.

In a phase 1 study, the investigational therapy known as cabotegravir ultra long-acting (CAB-ULA), showed positive pharmacokinetic, tolerability, and safety data supporting a prospective move to the next stage of clinical development.

Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis

From the ongoing CROI meeting, the FDA approved antiretroviral was studied over a 2-year period and showed treatment benefit.

The new indication for bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF (Biktarvy) is for patients with suppressed viral loads, pre-existing resistance.

Phase 3 study shows ART treatment in maintaining viral load suppression

In a case report, a patient with HIV with active multiple sclerosis showed reduced disease activity with tenofovir-containing antiretrovirals, suggesting potential MS treatment benefits.

Study sheds light on the evolving landscape of HIV-related mortality since the advent of antiretroviral therapy (ART).

A study compared COVID-19 vaccination rates and found people with HIV (PWH) had a lower rate of completing the primary vaccination series.

People who inject drugs (PWID) are at a higher risk for hepatitis C and HIV. A new study examined point of care initiatives and how to better support this population with intervention efforts.

This week a new vaccine for HIV is under development, a COVID-19 vaccine receives WHO emergency approval, and several local US health departments receive funding to combat antimicrobial resistance.

A new study warns an increase in costs could lead to new infections.

Infants with HIV could be spared from requiring lifetime ART if treated within hours of birth to disrupt formation of HIV viral reservoirs.

Therapy development, management improvements, and public health initiatives have all helped to change the trajectory of health outcomes for many, but still millions of people remain behind and are not in the continuum of care.

Salem Hospital faces a class action lawsuit over potential hepatitis and HIV exposure to hundreds of patients. The lawsuit alleges negligence and emotional distress, with the hospital claiming a minimal infection risk.

Learning about these barriers is the first step to overcoming them.

Emergency departments (EDs) are an important entry point into the health care system and have been identified as a location with opportunity for increased HIV diagnosis and management.

The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.

This action paves the way for this long-acting injectable to be used in several countries on the European continent.

Unique challenges can affect the success of the shift from pediatric to adult care settings.